Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.

[1]  Minfeng Chen,et al.  Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex , 2021, Frontiers in Medicine.

[2]  M. Sahin,et al.  Tuberous Sclerosis Complex: A review of the past, present and future. , 2020, Turkish journal of medical sciences.

[3]  Hao Sun,et al.  Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial , 2018, Orphanet Journal of Rare Diseases.

[4]  Y. Pei,et al.  Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). , 2016, Urology.

[5]  B. Korf,et al.  The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[7]  M. Wataya-Kaneda,et al.  A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity , 2011, The British journal of dermatology.

[8]  E. Thiele,et al.  Tuberous Sclerosis Complex: Diagnostic Challenges, Presenting Symptoms, and Commonly Missed Signs , 2011, Pediatrics.

[9]  S. Camposano,et al.  The natural history of epilepsy in tuberous sclerosis complex , 2009, Epilepsia.

[10]  A. Kistler,et al.  The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis , 2008, The British journal of dermatology.

[11]  R. Schwartz,et al.  Tuberous sclerosis complex: advances in diagnosis, genetics, and management. , 2007, Journal of the American Academy of Dermatology.

[12]  A. Schwarz,et al.  Side effects of sirolimus. , 2006, Transplantation proceedings.

[13]  F. DiMario.  Brain Abnormalities in Tuberous Sclerosis Complex , 2004, Journal of child neurology.

[14]  E. Thiele.  Managing Epilepsy in Tuberous Sclerosis Complex , 2004, Journal of child neurology.

[15]  S Povey,et al.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. , 1997, Science.

[16]  H. Per,et al.  Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis , 2017, Indian journal of dermatology, venereology and leprology.

[17]  S. Segal,et al.  Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.